Breaking Finance News

Kamada Ltd (NASDAQ:KMDA) has been upgraded to Hold in a statement by TheStreet earlier today.

Yesterday Kamada Ltd (NASDAQ:KMDA) traded -1.53% lower at $5.15. The company’s 50-day moving average is $4.61 and its 200-day moving average is $4.04. The last closing price is up 27.63% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. 35,014 shares of the stock traded hands, up from an average trading volume of 16,336

TheStreet has upgraded Kamada Ltd (NASDAQ:KMDA) to Hold in a report released on 9/26/2016.

Previously on 11/13/2015, Jefferies & Co reported on Kamada Ltd (NASDAQ:KMDA) reduced the target price from $8.00 to $7.00. At the time, this indicated a possible upside of 0.77%.

See Chart Below

Kamada Ltd (NASDAQ:KMDA)

Kamada Ltd has a 52 week low of $3.24 and a 52 week high of $5.34 The company’s market cap is currently $0.

General Information About Kamada Ltd (NASDAQ:KMDA)

Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company's product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy. Its product line also comprises Protosol to reduce blood loss in patients undergoing cardiac surgery; Heparin sodium injection for coagulation inhibition and prophylaxis of thromboembolic diseases and Heparin Lock Flush to maintain potency of intravenous injection device among other.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.